Autolus Therapeutics Announces Restructuring and 13% Workforce Reduction

Key Facts

1Autolus Therapeutics announced an operational efficiency initiative including a headcount reduction of approximately 13%.

2The company reiterated its full year 2026 AUCATZYL net product revenue guidance of $120 million to $135 million.

3The company plans to double manufacturing for commercial and clinical patients in 2026 while shifting to a positive gross margin.

Autolus Therapeutics has announced a strategic operational efficiency initiative that includes a headcount reduction of approximately 13%. This restructuring plan aims to lower operating expenses and accelerate the path to profitability for its acute lymphoblastic leukemia (ALL) business. Alongside the cuts, the company reiterated its full-year 2026 net product revenue guidance for AUCATZYL, projected between $120 million and $135 million. Autolus also plans to double its manufacturing capacity for both commercial and clinical patients by 2026 while shifting toward positive gross margins. These measures reflect management's commitment to optimizing financial resources to support the commercial scale-up of its T-cell therapies. Investors are closely monitoring whether this restructuring can successfully balance cost-cutting with sustained innovation and growth.